Efficacy of Point Of Service Testing in MBC

Status unconfirmed · Not applicable

Conditions studied: Metastatic Cancer, Breast Cancer

In brief

This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.

Key facts

Study ID

NCT03983577

Run by

University of Kansas Medical Center

People needed

100

Starts

2019-06-11

Expected to finish

2025-08-01

Last updated by the study team

2023-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent.
• Able to speak and read in the English language.
• Have a diagnosis of human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer.
• Participants must be enrolled in the parent registry study.

You may not qualify if…

• Genetic testing for a breast cancer gene (BRCA) BRCA1 and BRCA2 mutation completed after 2013 or any BRCA 1 and BRCA2 testing with large rearrangement testing. Prior genetic counseling is allowed.
• Psychiatric illness/social situations that would limit compliance with study requirements.

Where it is running

• The University of Kansas Cancer Center, Westwood Campus — Kansas City, Kansas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.